Our results showed that MUC6 tumor expression was associated with a better prognosis in patients with well- to moderately differentiated tumors, whereas CK17 or CD10 tumor expression was associated with worse prognosis in patients with poorly differentiated tumors. Here, MUC6 is linked to neoplasm.